title: A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy.
abstract: OBJECTIVE
  To assess the effects of medroxyprogesterone acetate on bone density in women who have had a hysterectomy.
  
  
  METHODS
  Randomised, double-blind, placebo-controlled trial of medroxyprogesterone acetate 10 mg, 20 mg or placebo as an adjunct to oestrogen therapy.
  
  
  METHODS
  One hundred and twenty-three women, aged 18 to 45 years and currently receiving daily oestrogen, who presented at a university-based rheumatology practice.
  
  
  METHODS
  The women were randomly assigned to receive either medroxyprogesterone acetate 10 mg, 20 mg or placebo daily beginning on day 15 of each month for one year. Forty-one women were randomised into each group.
  
  
  METHODS
  The primary outcome measurement was the percentage of change from baseline in bone mineral density of the lumbar spine (L2-L4). Secondary outcome measures included differences in femoral neck bone density, cholesterol and triglyceride levels between groups.
  
  
  RESULTS
  At one year, change in bone mineral density did not differ between either the treatment or placebo groups. Medroxyprogesterone acetate 20 mg and 10 mg led to statistically significant reductions in very low density lipoprotein cholesterol, total triglycerides, and very low density lipoprotein triglycerides when compared with placebo. Medroxyprogesterone acetate 20 mg also led to a statistically significant reduction in high density lipoprotein cholesterol, high density lipoprotein-2 cholesterol, and high density lipoprotein-2 triglycerides.
  
  
  CONCLUSIONS
  Medroxyprogesterone acetate at either dose as an adjunct to oestrogen did not improve bone mineral density at one year when compared with placebo. Medroxyprogesterone acetate 10 mg may not adversely affect lipids. Medroxyprogesterone acetate 20 mg, however, did reduce high density lipoprotein cholesterol and therefore may increase cardiovascular risk.
authors.affiliation: Department of Medicine, St Joseph's Hospital.
authors.forename: J D
authors.initials: JD
authors.lastname: Adachi
authors.forename: E J
authors.initials: EJ
authors.lastname: Sargeant
authors.forename: M A
authors.initials: MA
authors.lastname: Sagle
authors.forename: D
authors.initials: D
authors.lastname: Lamont
authors.forename: P D
authors.initials: PD
authors.lastname: Fawcett
authors.forename: W G
authors.initials: WG
authors.lastname: Bensen
authors.forename: M
authors.initials: M
authors.lastname: McQueen
authors.forename: D J
authors.initials: DJ
authors.lastname: Nazir
authors.forename: C H
authors.initials: CH
authors.lastname: Goldsmith
mesh_terms: D000293:Adolescent; D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D008076:Cholesterol, HDL / Q000097:blood; D004311:Double-Blind Method; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008079:Lipoproteins, VLDL / Q000097:blood; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D004966:Estrogens, Conjugated (USP); D008079:Lipoproteins, VLDL; D014280:Triglycerides; D017258:Medroxyprogesterone Acetate